Incyte | INCY - EPS Earnings Per Share


Incyte reported $-3.6 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 -3.60 1.98 2.26 Oct/29
FY2026Q2 Jun/2026 3.09 1.99 1.57 Jul/28
FY2026Q1 Mar/2026 1.81 1.42 1.16 Apr/28
FY2025Q4 Dec/2025 1.80 1.93 1.43 Feb/10
FY2025Q3 Sep/2025 2.26 1.58 1.07 Oct/28




Eps Change Date
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
Agenus USD 1.02 1.32 Mar/2026
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
BioCryst Pharmaceuticals USD 0.3 0.87 Jun/2026
Biogen USD 2.62 0.98 Sep/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Bristol-Myers Squibb USD 1.35 0.69 Sep/2026
Eli Lilly USD 7.48 0.9 Sep/2026
Exelixis USD 0.94 0.03 Sep/2026
Gilead Sciences USD 2.55 9.3 Sep/2026
Incyte USD -3.6 6.69 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
MacroGenics USD 0.31 0.89 Jun/2026
Merck USD 2.49 2.62 Sep/2026
Moderna USD 0.38 2.35 Sep/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
Novartis USD 2.46 0.05 Sep/2026
Novartis USD 0.63 1.36 Sep/2026
Pfizer USD 0.87 0.1 Sep/2026
PTC Therapeutics USD -0.62 1.54 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026